PMV Pharmaceuticals, Inc. (PMVP) is a leading precision oncology company in the biopharmaceutical industry that is passionate about providing innovative solutions to cancer treatment. This company is focused on the discovery and development of targeted therapies for cancer patients with specific, unaddressed genetic mutations. PMVP is headquartered in Cranbury, New Jersey.
PMV Pharmaceuticals was founded in 2014 by Dr. David Mack, Dr. Leona Ling, and Dr. Michael Farzan. Together, they wanted to revolutionize cancer treatment through the development of first-in-class p53 and p53 pathway modulators. The p53 gene, also known as the "guardian of the genome", acts as a significant barrier to tumor growth. Defects in the p53 gene are known to drive many types of cancers. PMVP strives to genetically correct these defects with their innovative therapies and drugs, paving the way for more effective cancer treatments.
PMV Pharma has developed a wide array of novel, small-molecule drugs that activate the p53 pathway. This is a quantum leap in cancer therapy that has gained significant attention in the medical community. Their most advanced drug in development is PC14586, targeted towards cancers with a specific p53 mutation. This drug is poised to become a breakthrough for patients with cancers that have been challenging to treat in the past.
The company operates on a strong philosophy of scientific rigor and creativity, partnering with leading academic, clinical, and business communities to fuel their innovative approach. The company's leadership is composed of industry veterans with diverse backgrounds in biotechnology, genetics, and pharmaceuticals, bringing a wealth of expertise to the company's operations.
PMV Pharmaceuticals went public in September 2020, with the aim to secure more financial resources for its R&D activities. Its shares are currently traded on the Nasdaq Global Select Market under the ticker "PMVP."
Despite being a relatively young company, PMVP has significantly impacted the fight against cancer by pushing the boundaries of scientific knowledge, and exemplifies the potential impact of precision medicine in cancer therapy. It's a company that truly lives up to its mission of defending the genome and defeating cancer.